|
Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of Genomics and Proteomic Sciences. There he spearheaded an initiative to create a platform for comprehensively characterizing (phenotyping) genetically modified mice and ran the collaboration involving a third party partnership to build it. This effort involved working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.From 1993 to 1999, Dr. Reaume worked as a research scientist at Cephalon where he was principally involved in creating animal models of neurodegenerative disease. During this time Dr. Reaume worked closely on a number of projects with Dr. Saporito, co-founder of Melior. In addition to Dr. Reaume's research activities at Cephalon, he identified and helped coordinate three in-licensing opportunities.In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management. He received his PhD in genetics from the University of Connecticut in 1990. | 